Safety of tiagabine: Summary of 53 trials

Epilepsy Research

Volumn 33, Issue 2-3, 1999, Pages 235-246

  Leppik, Ilo E ^a   Gram, Lennart ^a   Deaton, Roger ^a   Sommerville, Kenneth W ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Epilepsy; GABA; Safety; TGB

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR; ANTICONVULSIVE AGENT; PLACEBO; TIAGABINE;

ADOLESCENT; ADULT; AGED; AMBLYOPIA; ARTICLE; CHILD; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG SAFETY; FEMALE; FOCAL EPILEPSY; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROLOGIC DISEASE; PRIORITY JOURNAL; SPEECH DISORDER;

ADOLESCENT; ADULT; AGED; ANTICONVULSANTS; CHILD; CLINICAL TRIALS; DOSE-RESPONSE RELATIONSHIP, DRUG; EPILEPSY; FEMALE; HUMANS; INCIDENCE; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; NEOPLASMS; NERVOUS SYSTEM; NIPECOTIC ACIDS; OSMOLAR CONCENTRATION; OVERDOSE; PREGNANCY; SAFETY;

EID: 0033034045     PISSN: 09201211     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0920-1211(98)00094-1     Document Type: Article

References (16)

1. American Cancer Society, 1995. National Health Statistics. American Cancer Society, New York, USA.
2. Anon., 1989. COSTART Coding symbols for Thesaurus of Adverse Reaction Terms, 3rd ed. Department of Health and Human Services, Food and Drug Administration, Center for Drugs and Biologies, Rockville, Maryland.
3. Anon., 1997a. Gabapentin (Neurontin®) product labeling. In: Physician's Desk Reference®. Medical Economics Data Production Company, Montvale, New Jersey, pp. 1978-1981.
4. Anon., 1997b. Lamotrigine (Lamictal®) product labeling. In: Physician's Desk Reference®, Medical Economics Data Production Company, Montvale, New Jersey, pp. 1105-1110.
5. Anon., 1997c. Baclofen (Lioresal®) product labeling. In: Physician's Desk Reference®. Medical Economics Data Production Company, pp. 847-848.
6. Ben-Menachem E. International experience with tiagabine add-on therapy. Epilepsia. 36(Suppl. 6):1995;S14-21.
7. Braestrup C., Nielsen E.B., Sonnewald U.et al. NO-328 binds with high affinity to the brain GABA uptake carrier. J. Neurochem. 54:1990;639-647.
8. Coenen A.M.L., Blezer E.H.M., Van Luijtelaar E.L.J.M. Effects of the GABA-uptake inhibitor tiagabine on electroencephalogram, spike-wave discharges and behaviour of rats. Epilepsy Res. 21:1994;89-94.
9. Enna, S.J., 1981a. Neuropharmacological and clinical aspects of GABA. In: Palmer, G. (Ed.), Neuropharmacology of Central Nervous System and Behavioral Disorders. Academic Press, New York, p. 507.
10. Enna S.J. GABA receptor pharmacology - functional considerations. Biochem. Pharmacol. 30:1981;907-914.
11. Fahn, S., 1976. GABA. In: Chase, T., Tower, D. (Eds.), GABA in Nervous System Function. Raven Press, New York, p. 169.
12. Krogsgaard-Larsen P. GABA synaptic mechanisms: stereochemical and conformational requirements. Med. Res. Rev. 8:1988;27-56.
13. Leppik I. Intractable epilepsy in adults. Epilepsy Res. 5(Suppl.):1992;7-11.
14. McKenna, P.J., Kane, K.M., Parrish, K., 1985. Psychotic syndromes in epilepsy. Am. J. Psych. 142, 895-904.
15. Schousboe, A., Larsson, O.M., Korgsaard-Larsen, P., 1991. GABA uptake inhibitors as anticonvulsants. In: Tunnicliff, G., Raess, B.U. (Eds.), GABA Mechanisms in Epilepsy. Wiley Liss, New York, p. 165.
16. Walton N.Y., Gunawan S., Treiman D.M. Treatment of experimental status epilepticus with the GABA uptake inhibitor, tiagabine. Epilepsy Res. 19:1994;237-244.